News
Amgen and AstraZeneca say Tezspire shows proof of concept in COPD trial reported at ATS2024, despite missing primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback